Karyopharm Therapeutics (KPTI) News Today → Trump Reveals Conspiracy Behind Fed-Controlled Digital Currency. (From Monetary Gold) (Ad) Free KPTI Stock Alerts $1.12 -0.01 (-0.44%) (As of 10:03 AM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 15 at 3:26 AM | americanbankingnews.comKaryopharm Therapeutics Inc. (NASDAQ:KPTI) Receives Average Rating of "Moderate Buy" from AnalystsMay 15 at 3:24 AM | marketbeat.comKaryopharm Therapeutics Inc. (NASDAQ:KPTI) Given Average Recommendation of "Moderate Buy" by AnalystsKaryopharm Therapeutics Inc. (NASDAQ:KPTI - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the five brokerages that are presently covering the firm, Marketbeat.com reports. Two research analysts have rated the stock with a hold rating and three have issued a buy ratinMay 13 at 3:34 AM | americanbankingnews.comQ3 2024 Earnings Forecast for Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Issued By Leerink PartnrsMay 13 at 3:34 AM | americanbankingnews.comKaryopharm Therapeutics Inc. to Post Q3 2024 Earnings of ($0.31) Per Share, HC Wainwright Forecasts (NASDAQ:KPTI)May 13 at 2:50 AM | americanbankingnews.comKaryopharm Therapeutics' (KPTI) "Buy" Rating Reaffirmed at HC WainwrightMay 10, 2024 | seekingalpha.comKPTI Karyopharm Therapeutics Inc.May 10, 2024 | markets.businessinsider.comBuy Rating for Karyopharm Therapeutics: Debt Restructuring and Promising Xpovio Studies Drive Optimistic OutlookMay 10, 2024 | finance.yahoo.comKaryopharm Therapeutics First Quarter 2024 Earnings: EPS Beats Expectations, Revenues LagMay 9, 2024 | markets.businessinsider.comOptimistic Buy Rating for Karyopharm Therapeutics Amidst Financial Stability and Promising Clinical TrialsMay 9, 2024 | finance.yahoo.comKaryopharm Therapeutics Inc. (NASDAQ:KPTI) Q1 2024 Earnings Call TranscriptMay 9, 2024 | marketbeat.comKaryopharm Therapeutics (NASDAQ:KPTI) Stock Rating Reaffirmed by HC WainwrightHC Wainwright reiterated a "buy" rating and issued a $8.00 price target on shares of Karyopharm Therapeutics in a report on Thursday.May 9, 2024 | finance.yahoo.comKaryopharm Therapeutics Inc (KPTI) Q1 2024 Earnings Call Transcript Highlights: Navigating ...May 8, 2024 | finance.yahoo.comQ1 2024 Karyopharm Therapeutics Inc Earnings CallMay 8, 2024 | finanznachrichten.deKaryopharm Therapeutics Inc.: Karyopharm Reports First Quarter 2024 Financial Results and Highlights Recent Company ProgressMay 8, 2024 | finance.yahoo.comKaryopharm Therapeutics Reports Q1 2024 Financial Results: A Detailed ReviewMay 8, 2024 | markets.businessinsider.comKaryopharm Therapeutics Inc. Q1 Loss increases, but beats estimatesMay 8, 2024 | prnewswire.comKaryopharm to Participate at the 2024 RBC Capital Markets Global Healthcare ConferenceMay 8, 2024 | investorplace.comKPTI Stock Earnings: Karyopharm Therapeutics Beats EPS, Misses Revenue for Q1 2024May 8, 2024 | prnewswire.comKaryopharm Reports First Quarter 2024 Financial Results and Highlights Recent Company ProgressMay 8, 2024 | prnewswire.comKaryopharm Announces Significant Refinancing Transactions and Amended Royalty Agreement Extending Vast Majority of Its Debt Maturities into 2028 and 2029May 3, 2024 | marketbeat.comKaryopharm Therapeutics (KPTI) Scheduled to Post Earnings on WednesdayKaryopharm Therapeutics (NASDAQ:KPTI) will be releasing earnings before the market opens on Wednesday, May 8, Zacks reports.May 2, 2024 | prnewswire.comKaryopharm to Report First Quarter 2024 Financial Results on May 8, 2024May 1, 2024 | prnewswire.comKaryopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 24, 2024 | prnewswire.comKaryopharm Announces Presentations in Endometrial Cancer and Myelofibrosis at the 2024 American Society of Clinical Oncology Annual MeetingApril 1, 2024 | prnewswire.comKaryopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 15, 2024 | finance.yahoo.comKPTI Apr 2024 5.000 callMarch 15, 2024 | finance.yahoo.comKPTI Apr 2024 1.500 putMarch 14, 2024 | businesswire.comOnco360 Selected as the Preferred National Specialty Pharmacy Partner for XPOVIO ® (selinexor)March 6, 2024 | finance.yahoo.comKaryopharm to Participate at Barclays 26th Annual Global Healthcare and Leerink Partners Global Biopharma ConferencesMarch 5, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Karyopharm Therapeutics (KPTI) and Siemens Healthineers AG (OtherSEMHF)March 5, 2024 | finance.yahoo.comInsider Sell: President and CEO Richard Paulson Sells 99,844 Shares of Karyopharm Therapeutics ...March 2, 2024 | seekingalpha.comKaryopharm Therapeutics Inc. (KPTI) Q4 2023 Earnings Call TranscriptMarch 1, 2024 | prnewswire.comKaryopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 1, 2024 | marketbeat.comKaryopharm Therapeutics (NASDAQ:KPTI) Releases Quarterly Earnings Results, Misses Expectations By $0.07 EPSKaryopharm Therapeutics (NASDAQ:KPTI - Get Free Report) announced its earnings results on Thursday. The company reported ($0.36) earnings per share for the quarter, missing the consensus estimate of ($0.29) by ($0.07). The company had revenue of $33.75 million during the quarter, compared to analyst estimates of $33.50 million. During the same period in the prior year, the company earned ($0.43) earnings per share.March 1, 2024 | finance.yahoo.comKaryopharm Therapeutics Inc. (NASDAQ:KPTI) Q4 2023 Earnings Call TranscriptMarch 1, 2024 | marketbeat.comKaryopharm Therapeutics Inc. (NASDAQ:KPTI) Given Consensus Recommendation of "Moderate Buy" by AnalystsShares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI - Get Free Report) have received a consensus rating of "Moderate Buy" from the five brokerages that are presently covering the stock, Marketbeat Ratings reports. Two research analysts have rated the stock with a hold recommendation and three haveMarch 1, 2024 | marketbeat.comBrokers Offer Predictions for Karyopharm Therapeutics Inc.'s FY2025 Earnings (NASDAQ:KPTI)Karyopharm Therapeutics Inc. (NASDAQ:KPTI - Free Report) - Stock analysts at Leerink Partnrs issued their FY2025 earnings per share estimates for Karyopharm Therapeutics in a research note issued to investors on Thursday, February 29th. Leerink Partnrs analyst J. Chang expects that the company wiMarch 1, 2024 | marketbeat.comKaryopharm Therapeutics (NASDAQ:KPTI) PT Lowered to $8.00 at HC WainwrightHC Wainwright decreased their price objective on shares of Karyopharm Therapeutics from $10.00 to $8.00 and set a "buy" rating for the company in a research report on Friday.February 29, 2024 | fool.comKaryopharm Therapeutics (KPTI) Q4 2023 Earnings Call TranscriptFebruary 29, 2024 | finance.yahoo.comQ4 2023 Karyopharm Therapeutics Inc Earnings CallFebruary 29, 2024 | finanznachrichten.deKaryopharm Therapeutics Inc.: Karyopharm Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Company ProgressFebruary 29, 2024 | msn.comKaryopharm Therapeutics GAAP EPS of -$0.36 misses by $0.07, revenue of $33.7M beats by $0.08MFebruary 29, 2024 | markets.businessinsider.comKaryopharm Therapeutics Inc. Q4 Loss misses estimatesFebruary 29, 2024 | finance.yahoo.comKaryopharm Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Company ProgressFebruary 28, 2024 | benzinga.comKaryopharm Therapeutics's Earnings: A PreviewFebruary 27, 2024 | finance.yahoo.comKPTI Mar 2024 1.000 putFebruary 27, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: FibroGen (FGEN), Karyopharm Therapeutics (KPTI) and Day One Biopharmaceuticals (DAWN)February 25, 2024 | ca.finance.yahoo.comKPTI Mar 2024 1.500 callFebruary 25, 2024 | investorplace.com7 Biotech Penny Stocks on the Verge of Clinical Trial VictoryFebruary 23, 2024 | marketbeat.comKaryopharm Therapeutics (KPTI) to Release Quarterly Earnings on ThursdayKaryopharm Therapeutics (NASDAQ:KPTI) will be releasing earnings before the market opens on Thursday, February 29, Zacks reports. Get Karyopharm Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KPTI and its competitors with MarketBeat's FREE daily newsletter. Email Address A ‘DeFi Summer’ Projected! (Ad)Top analysts are predicting DeFi coins to see massive gains in the coming months… During this dubbed ‘DeFi Summer…’ A coin that has been called the “DeFi pioneer” is poised to shoot up 3-7x! Just click here to learn how you can access this coin right now. KPTI Media Mentions By Week KPTI Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. KPTI News Sentiment▼0.210.55▲Average Medical News Sentiment KPTI News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. KPTI Articles This Week▼182▲KPTI Articles Average Week Get Karyopharm Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KPTI and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Vistagen Therapeutics News Today Abeona Therapeutics News Today Immunic News Today Nuvectis Pharma News Today Cartesian Therapeutics News Today Amylyx Pharmaceuticals News Today Coya Therapeutics News Today FibroGen News Today Syros Pharmaceuticals News Today Sagimet Biosciences News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:KPTI) was last updated on 5/16/2024 by MarketBeat.com Staff From Our PartnersThe #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique WaySmallcaps DailyWATCH: The Truth About InflationBirch GoldRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportDemocrats Push to Replace Dollar With Digital Coin, Control Currency.Monetary GoldDoes this make you sick?Allegiance GoldTop 5 AI Stocks to Buy for 2024Market Moving Trends Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Karyopharm Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
